Indian Journal of Medical Microbiology IAMM  | About us |  Subscription |  e-Alerts  | Feedback |  Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Ahead of Print | Current Issue | Archives | Search | Instructions  
Users Online: 561 Official Publication of Indian Association of Medical Microbiologists 
  Search
 
 ~ Next article
 ~ Previous article 
 ~ Table of Contents
  
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~  Article in PDF (181 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

 
 ~  Abstract
 ~  The need for alt...
 ~  Development and ...
 ~  Conclusions
 ~  Acknowledgements
 ~  Laboratory chara...
 ~  Comparison of IF...
 ~  References
 ~  Article Figures
 ~  Article Tables

 Article Access Statistics
    Viewed26104    
    Printed807    
    Emailed47    
    PDF Downloaded1550    
    Comments [Add]    
    Cited by others 63    

Recommend this journal

 


 
REVIEW ARTICLE
Year : 2005  |  Volume : 23  |  Issue : 3  |  Page : 151-158
 

Alternatives to the tuberculin skin test: Interferon-γ assays in the diagnosis of Mycobacterium Tuberculosis infection


Division of Epidemiology, University of California, Berkeley, CA 94720,and Division of Pulmonary & Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, USA

Date of Submission16-Nov-2004
Date of Acceptance22-Mar-2005

Correspondence Address:
M Pai
Division of Epidemiology, University of California, Berkeley, CA 94720,and Division of Pulmonary & Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0255-0857.16585

Rights and Permissions

 ~ Abstract 

For nearly a century, there were no alternatives to the tuberculin skin test (TST) for diagnosing latent tuberculosis infection. Because of advances in immunology and genomics, for the first time, an alternative has emerged in the form of T cell based interferon-g (IFN-g) assays, a new generation of in vitro tests of cellular immunity. These assays measure cell mediated immune response by quantifying IFN-g released by T cells in response to stimulation by Mycobacterium tuberculosis antigens. Although early versions of IFN-g assays used purified protein derivative (PPD) as the stimulating antigen, newer versions use antigens that are significantly more specific to M. tuberculosis. These specific antigens include ESAT-6 and CFP-10. These proteins, encoded by genes located within the region of difference 1 (RD1) segment of the M. tuberculosis genome, are more specific to M. tuberculosis than PPD because they are not shared with any BCG substrains or several nontuberculous mycobacterial species. A review of current evidence on the performance of IFN-g assays and TST suggests that both the TST and IFN-g assays have advantages and limitations, and both tests appear to be useful at this time. The emergence of IFN-g assays is a much anticipated, welcome development that has, for the first time, increased the choice of tests available for diagnosing latent tuberculosis infection. Because both tests have their strengths and limitations, the decision to select one over the other will depend on the population, the goal of testing, and the resources available. To fully evaluate the utility of IFN-g assays in high burden countries such as India, long-term cohort studies are needed to determine the association between positive IFN-g results and the subsequent risk of active disease.


Keywords:  Tuberculosis, interferon-γ assays, tuberculin skin test, diagnostic accuracy


How to cite this article:
Pai M. Alternatives to the tuberculin skin test: Interferon-γ assays in the diagnosis of Mycobacterium Tuberculosis infection. Indian J Med Microbiol 2005;23:151-8

How to cite this URL:
Pai M. Alternatives to the tuberculin skin test: Interferon-γ assays in the diagnosis of Mycobacterium Tuberculosis infection. Indian J Med Microbiol [serial online] 2005 [cited 2017 Sep 26];23:151-8. Available from: http://www.ijmm.org/text.asp?2005/23/3/151/16585


The World Health Organization estimates that one third of the world′s population is infected with Mycobacterium tuberculosis.[1] This enormous reservoir of infected individuals presents a major hurdle for global tuberculosis (TB) control. In low TB endemic countries, targeted testing for latent tuberculosis infection (LTBI) and treatment is a key part of the TB control strategy. In high burden countries such as India, diagnosis and treatment of active tuberculosis receives greater priority; testing for LTBI is usually done only in selected high risk groups such as children, household contacts, and individuals with Human Immunodeficiency Virus (HIV) infection. How is LTBI diagnosed and what are the diagnostic options available?


 ~ The need for alternatives to the tuberculin skin test Top


The tuberculin skin test (TST) was, until recently, the only test available for the diagnosis of LTBI.[2],[3],[4],[5],[6],[7] The TST measures delayed type hypersensitivity response to the purified protein derivative (PPD). A major limitation of PPD is the fact that it is a crude mixture of several antigens, many of which are shared among M. tuberculosis , M. bovis BCG, and several non-tuberculous mycobacteria (NTM). As a result, a positive TST result could potentially be due to true infection with M. tuberculosis , prior BCG vaccination, or due to exposure to NTM.[2],[5],[6],[7],[8] Separating these components of the tuberculin response is not easy and is partly the basis for using risk stratified cut points in different population subgroups.[8] It is well known that the TST has lower specificity in populations with high BCG coverage and NTM exposure. [2],[3],[4],[5],[6],[7],[9] Also, its sensitivity may be low due to anergy in individuals with depressed immunity (e.g. HIV infection). [2],[3],[4],[5],[6],[7],[9] Further, the administration and reading of TST poses several unique problems - under reading, within and between reader variability, digit preference, the need for trained personnel to read the test results, and the requirement for patients to return for the purpose test reading. On account of all these limitations, there has always been a need to develop alternative tests for latent TB infection. Strangely, despite these limitations, for a long time little research went into the development of alternative tests for latent TB. This neglect is also noticeable in the persistent lack of new vaccines and drugs for tuberculosis.[52]


 ~ Development and evolution of interferon-γ assays Top


The successful sequencing of M. tuberculosis and M. bovis genomes has lead to the emergence of the field of comparative genomics (i.e., analysis and comparison of genomes from different species). Recent advances in genomics, molecular biology, and immunology have led to a promising generation of alternative tests such as T cell based, in vitro, interferon-γ (IFN-γ) assays. [9],[10],[11],[12] The IFN-γ assay is based on the concept that T cells of individuals sensitized with M. tuberculosis release interferon-γ (IFN-γ), a Th-1 cytokine, when they reencounter mycobacterial antigens [Figure - 1].

This process, unlike the TST, occurs ex vivo . A high level of IFN-γresponse is likely to indicate previous sensitization with M. tuberculosis , but does not necessarily imply active disease. In this respect, the IFN-γassay is similar to the TST. It cannot easily distinguish between latent infection and active disease.

While early versions of IFN-γassays employed PPD as the stimulating antigen, it became clear that such assays will have the same specificity problems seen with the PPD based TST.[12] Extensive basic science research lead to the development of newer assays that employ antigens that are highly specific to M. tuberculosis . These antigens include the early secretory antigenic target 6 (ESAT-6) and culture filtrate protein (CFP-10). These low molecular weight proteins, encoded within the region of difference 1 (RD1) of the M. tuberculosis genome, are more specific to M. tuberculosis than PPD, and they are not shared with the BCG sub strains and most NTM species (with the exception of M. kansasii , M. marinum and M. szulgai ). [9],[10],[11] Tests based on these TB specific antigens are called RD1 based IFN-γassays. With the introduction of RD1 based assays, PPD based IFN-γassays are already being phased out.

Two RD1 based IFN-γassays are now available commercially. The QuantiFERON-TB ® assay (Cellestis Limited, Carnegie, Australia) was the first IFN-γassay to become commercially available. This whole blood test was approved by the US Food and Drug Administration (FDA) in 2001 and is available in many countries.[13] However, this first generation assay measures IFN-γresponse to PPD and thus is susceptible to the same specificity problems as the TST.[9] This PPD based assay is currently being replaced by an enhanced assay, the QuantiFERON-TB-Gold ® test (which uses ESAT-6 and CFP-10 in place of PPD). This new assay is currently available in Europe, and was approved by the US FDA in December 2004.

Other assays, including those using the enzyme linked immunospot (ELISPOT) to detect IFN-γresponse, have also been evaluated in different settings.[9],[11],[12] The T SPOT-TB ® (Oxford Immunotec, Oxon, UK) is the second assay to reach commercial development. This assay, performed using peripheral blood mononuclear cells (PBMC), employs ESAT-6 and CFP-10, and detects the number of IFN-γproducing T cells using a sensitive ELISPOT technology. This test, currently available in Europe, is awaiting US FDA approval. In India, both QuantiFERON-TB Gold and T SPOT-TB assays have been evaluated in research settings, in rural[14] and urban populations.[15] However, these assays are currently not used in clinical practice in India.


 ~ Laboratory characteristics of IFN-γ assays Top


Although all IFN-γassays are cellular immune based tests that quantify IFN-γresponse, the operational and laboratory characteristics of these assays are quite variable [Figure - 2].[12]

The QuantiFERON-TB-Gold and T SPOT-TB, the two commercially available RD1-based tests, are quite different in their assay formats and laboratory procedures [Figure - 3] and [Figure - 4]. The incubation periods used in assays vary from short (16 - 24 hours in QuantiFERON-TB, and T SPOT-TB) to long (5 - 6 days in several in-house assays). Some assays use whole blood (QuantiFERON-TB), while others use PBMC (T SPOT-TB). The antigens used is PPD in some assays (first generation QuantiFERON-TB), while they are RD1 based in others (QuantiFERON-TB Gold, T SPOT-TB). While most assays use the ELISA format (QuantiFERON-TB), some use the ELISPOT format (T SPOT-TB) for IFN-γmeasurement. Assays also vary in the source and type of antigens used for stimulation - some use antigens whereas others use peptides (recombinant rESAT-6 peptides).

It is not clear at this time whether some assay characteristics are likely to increase test accuracy. For example, it is not clear whether assays that use longer incubation periods are likely to have higher sensitivity. Overnight incubation assays primarily detect immediate effector T cells that have already been activated in vivo , whereas in the longer incubation periods used in other assays, there is sufficient time in which to activate resting memory T cells as well. Similarly, there are no studies on whether the ELISPOT format is more or less sensitive than the ELISA method. It does appear that adding specific antigens and using them as "cocktails" or antigenic mixtures does increase sensitivity, without sacrificing specificity.[12] The technology of IFN-γassays is constantly evolving, and much effort is being directed toward the development of better TB specific antigens that can be used for both diagnostic purposes and the design of new vaccines.[9]


 ~ Comparison of IFN-γ assays with tuberculin skin testing Top


[Table - 1] presents a comparison of the performance and operational characteristics of IFN-γassays with the tuberculin skin test, based on the available, published evidence (extensively reviewed elsewhere[9],[12]. It must be kept in mind that this summary of evidence is likely to change as new studies on IFN-γassays are constantly advancing the state of the art. As seen in [Table - 1], the TST has moderate to high, but variable sensitivity and specificity, depending on the population screened.[2],[4],[5],[6],[16] Specificity of TST tends to vary more than sensitivity. Several longitudinal studies, including a large study from India,[17] have shown a positive association between TST response and subsequent risk of active TB.[2],[6],[17],[18] Therefore, although crude and imprecise, the TST has the ability to predict active TB among latently infected individuals. Several randomized trials have shown that treatment of LTBI, diagnosed on the basis of positive TST, reduces the risk of active TB by about 60%.[6],[8],[16],[19] This experimental evidence, in fact, has lead to the policy of targeted tuberculin testing and LTBI treatment (e.g. isoniazid for 6 - 9 months) in developed countries.[8]

Further, the TST is a simple test with low material costs that does not require a laboratory. It has, therefore, been extensively used even in resource limited settings for both clinical testing (in children) and epidemiological field studies.[5],[7] In India, several studies on annual risk of TB infection (ARI) have been conducted using TST.[5],[20]

Research evidence suggests that RD1 based IFN-γassays outperform the TST with respect to the following characteristics: higher specificity, better correlation with indirect measures of exposure to M. tuberculosis , and relatively less cross reactivity due to BCG vaccination and NTM infection.[9],[10],[11],[12],[13],[21] In terms of sensitivity, RD1 based IFN-γassays that use cocktails of specific antigens (a mixture of ESAT-6 and CFP-10) appear to be at least as sensitive as the PPD based TST.[12] The other advantages include rapidity, the need for only a single patient visit, avoidance of subjective and poorly reliable measurements such as skin induration, and the ability to perform repeat testing without boosting. There is limited evidence, based on one small study, of an association between IFN-γresponse to ESAT-6 and subsequent progression to active TB among contacts of TB patients.[22] To date, no clinical trial has demonstrated the efficacy of treatment on the basis of IFN-γassay results. In other words, we do not know if treatment of individuals positive by the IFN-γassay will prevent the development of active disease in future. A major limitation of IFN-γassays is their higher material costs and the need for laboratory infrastructure (the laboratory has to have the capacity to run ELISA or ELISPOT).[12] In India, although no formal costing studies have been conducted, the material cost of IFN-γassays may be 5 - 10 times higher than TST. This cost differential might be less striking in other settings (USA) where labor costs are significantly higher, making the TST, as a whole, an expensive test.[23]

Because of the lack of a gold standard for latent infection, it is impossible to accurately determine the sensitivity and specificity of IFN-γassays for the diagnosis of latent infection. Therefore, several studies have evaluated the agreement (concordance) between TST and IFN-γassays [Table - 2].

This approach avoids the use of TST, an imperfect test, as the gold standard. Most studies reported modest to high agreement (60% to 80%) between the two tests. The only Indian study to evaluate the agreement between TST and an IFN-γassay reported a high degree of agreement of 81%.[14] This study of 726 health care workers, conducted in a rural hospital in Sevagram, Maharashtra, compared the third generation QuantiFERON-TB Gold In Tube assay (RD1 based) with TST (1 TU dose of PPD RT23). This large study also showed that previous BCG vaccination had little impact on both TST and QuantiFERON-TB Gold results in adult health care workers.


 ~ Conclusions Top


Current evidence suggests that both the TST and IFN-γassays have advantages and limitations, and both tests appear to be useful. No single test, at this time, might suit all conditions. The emergence of IFN-γassays is a much anticipated development that has, for the first time, increased the diagnostic tools available for LTBI. It is, therefore, important to consider both tests as part of an expanding armamentarium of TB diagnostics. In this context, the decision to select one or the other will depend on the population, the goal of testing, and the resources available. For example, serial monitoring of health care workers (annual testing) is a key component of nosocomial TB control in many developed countries. In such settings, the RD1 based IFN-γassay might be a more appropriate test. It will eliminate the need for repeat visits and two step TST testing, avoid boosting, and minimize interpretational difficulties. Because of its higher specificity, IFN-γassays will be helpful in low endemic populations where cross reactivity due to BCG and NTM pose problems in TST interpretation. It is also likely to reduce false positives and enhance targeted LTBI treatment, particularly in low incidence settings. Cross reactivity due to BCG appears to be an important issue in some populations where BCG vaccination is not given at birth, but later on in life. Further, IFN-γassays may be helpful in screening populations such as HIV-infected individuals, homeless individuals, and injection drug users, where low return rates for TST reading is a major concern.

In high-burden and resource-limited settings such as India, where even access to simple technology such as sputum microscopy may be poor in some areas, the TST might continue to serve a useful purpose. In the Indian context, a 15 year follow up of 280,000 subjects from the south Indian BCG vaccine trial has showed that TST response is significantly associated with development of active TB.[17] This study and other Indian studies suggest that the TST remains a useful test.[5],[17],[20] Also, data from several studies in India suggest that BCG vaccination may not pose a major problem in the interpretation of TST results.[14],[24],[25] Recent nationwide tuberculin surveys in India, involving more than 100,000 children, have also shown the BCG does not substantially affect the estimation of annual risk of infection.[24],[25] However, BCG might adversely affect TST results in other populations, depending on BCG strain used, timing of vaccination, frequency, and time elapsed since vaccination.[38] It is therefore important to consider these issues carefully before selecting the appropriate test.

To fully evaluate the utility of IFN-γassays in high burden countries such as India, long term cohort studies are needed to determine the association between positive IFN-γresults and the subsequent risk of active TB. If these studies consistently demonstrate a strong association between positive IFN-γresults and risk of active TB, and if the effect is stronger than that of TST, this would indicate that IFN-γassays have a better ability to identify those at higher risk for progressing to active disease. It is also important to determine if treatment of individuals diagnosed to have LTBI using IFN-γassay will result in protection against development of active tuberculosis. These studies should help to settle the debate on whether IFN-γassays can replace the TST. For now, it is probably a good strategy to keep both TST and IFN-γassays on the LTBI diagnostic menu, and select the appropriate test based on the population, the purpose of testing, and the resources available.


 ~ Acknowledgements Top


This work was supported by the Fogarty AIDS International Training Program (1-D43-TW00003-16), and NIH/NIAID (R01 AI 34238). This article is partly based on a previously published systematic review on IFN-γassays (Pai M, et al. Lancet Infect Dis 2004;4:761-76). The author is grateful to SP Kalantri, P Narang, DK Mendiratta, R Joshi, and S Dogra, from the Mahatma Gandhi Institute of Medical Sciences, Sevagram, for their support with collaborative research projects.

 
 ~ References Top

1.Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282 :677-86.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Huebner RE, Schein MF, Bass JB, Jr. The tuberculin skin test. Clin Infect Dis 1993; 17 :968-75.  Back to cited text no. 2    
3.Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis 2002; 34 :365-70.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Bass JB, Jr. The tuberculin skin test. In : Field MJ, edn. Tuberculosis in the workplace. Washington, D.C.: National Academy Press; 2001. p. 179-88.  Back to cited text no. 4    
5.Chadha VK. Tuberculin test. Indian J Pediatr 2001; 68 :53-8.  Back to cited text no. 5  [PUBMED]  
6.Menzies RI. Tuberculin skin testing. In :Tuberculosis: a comprehensive international approach. Reichman LB, Hershfield ES, editors. New York: Marcel Dekker; 2000. p. 279-322.  Back to cited text no. 6    
7.Rieder HL. Epidemiologic basis of tuberculosis control. Paris: International Union Against Tuberculosis and Lung Disease, 1999.  Back to cited text no. 7    
8.American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 :221-47.  Back to cited text no. 8    
9.Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356 :1099-104.  Back to cited text no. 9  [PUBMED]  [FULLTEXT]
10.Barnes PF. Diagnosing latent tuberculosis infection: turning glitter to gold. Am J Respir Crit Care Med 2004; 170 :5-6.  Back to cited text no. 10  [PUBMED]  [FULLTEXT]
11.Lalvani A. Spotting latent infection: the path to better tuberculosis control. Thorax 2003; 58 :916-8.  Back to cited text no. 11  [PUBMED]  [FULLTEXT]
12.Pai M, Riley LW, Colford JM. Interferon-g assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4 :761-76.  Back to cited text no. 12    
13.Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52 :15-8.  Back to cited text no. 13    
14.Pai M, Gokhale K, Joshi R, Dogra S, Kalantri SP, Mendiratta DK, et al . Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood, interferon-g assay with tuberculin skin testing. JAMA 2005; 293 :2746-55.  Back to cited text no. 14    
15.Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, et al . Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001; 183 :469-77.  Back to cited text no. 15    
16.Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347 :1860-6.  Back to cited text no. 16  [PUBMED]  [FULLTEXT]
17.Radhakrishna S, Frieden TR, Subramani R. Association of initial tuberculin sensitivity, age and sex with the incidence of tuberculosis in south India: a 15-year follow-up. Int J Tuberc Lung Dis 2003; 7 :1083-91.  Back to cited text no. 17    
18.Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 2000; 4 :895-903.  Back to cited text no. 18  [PUBMED]  
19.Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3 :847-50.  Back to cited text no. 19  [PUBMED]  
20.Chadha VK. Epidemiological situation of tuberculosis in India. J Indian Med Assoc 2003; 101 :144-7.  Back to cited text no. 20  [PUBMED]  
21.Lein AD, Von Reyn CF. In vitro cellular and cytokine responses to mycobacterial antigens: Application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines. American Journal of the Medical Sciences 1997; 313 :364-71.  Back to cited text no. 21  [PUBMED]  [FULLTEXT]
22.Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, Eguale T, et al . Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002; 40 :704-6.  Back to cited text no. 22    
23.Lambert L, Rajbhandary S, Quails N, Budnick L, Catanzaro A, Cook S, et al . Costs of implementing and maintaining a tuberculin skin test program in hospitals and health departments. Infect Control Hosp Epidemiol 2003; 24 :814-20.  Back to cited text no. 23    
24.Chadha VK, Jaganath PS, Kumar P. Tuberculin sensitivity among children vaccinated with BCG under universal immunization programme. Indian J Pediatr 2004; 71 :1063-8.  Back to cited text no. 24  [PUBMED]  [FULLTEXT]
25.Chadha VK, Jagannatha PS, Kumar P. Can BCG-vaccinated children be included in tuberculin surveys to estimate the annual risk of tuberculous infection in India? Int J Tuberc Lung Dis 2004; 8 :1437-42.  Back to cited text no. 25  [PUBMED]  
26.American Thoracic Society. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med 2000; 161 :1376-95.  Back to cited text no. 26    
27.Arend SM, Andersen P, van Meijgaarden KE, Skjot RL, Subronto YW, van Dissel JT, et al . Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis 2000; 181 :1850-4.  Back to cited text no. 27    
28.Brock I, Munk ME, Kok-Jensen A, Andersen P. Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 2001; 5 :462-7.  Back to cited text no. 28  [PUBMED]  
29.Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 2004; 42 :2379-87.  Back to cited text no. 29  [PUBMED]  [FULLTEXT]
30.Chapman AL, Munkanta M, Wilkinson KA, Pathan AA, Ewer K, Ayles H, et al . Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16 :2285-93.  Back to cited text no. 30    
31.Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, et al . Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001; 163 :824-8.  Back to cited text no. 31    
32.Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al . Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170 :59-64.  Back to cited text no. 32    
33.Liebeschuetz S, Bamber S, Ewer K, Deeks JJ, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study. Lancet 2004.  Back to cited text no. 33    
34.Lein AD, von Reyn CF, Ravn P, Horsburgh CR, Jr. Alexander LN, Andersen P. Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis. Clin Diagn Lab Immunol 1999; 6 :606-9.  Back to cited text no. 34    
35.Munk ME, Arend SM, Brock I, Ottenhoff TH, Andersen P. Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. J Infect Dis 2001; 183 :175-6.  Back to cited text no. 35  [PUBMED]  [FULLTEXT]
36.Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, et al . Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001; 167 :5217-25.  Back to cited text no. 36    
37.Menzies D. What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us? Clin Infect Dis 2000; 31 :71-4.  Back to cited text no. 37  [PUBMED]  [FULLTEXT]
38.Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57 :804-9.  Back to cited text no. 38  [PUBMED]  [FULLTEXT]
39.Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170 :65-9.  Back to cited text no. 39  [PUBMED]  [FULLTEXT]
40.Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, et al . Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361 :1168-73.  Back to cited text no. 40    
41.Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, et al . Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001; 357 :2017-21.  Back to cited text no. 41    
42.Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR, et al . Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286 :1740-7.  Back to cited text no. 42    
43.Arend SM, van Meijgaarden KE, de Boer K, de Palou EC, van Soolingen D, Ottenhoff TH, et al . Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 2002; 186 :1797-807.  Back to cited text no. 43    
44.Daniel TM. The occupational tuberculosis risk of health care workers. In : Field MJ, edn. Tuberculosis in the workplace. Washington, D.C.: National Academy Press; 2001. p. 189-229.  Back to cited text no. 44    
45.Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. N Engl J Med 1995; 332 :92-8.  Back to cited text no. 45  [PUBMED]  [FULLTEXT]
46.World Health Organization. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. Geneva: World Health Organization, 1999.  Back to cited text no. 46    
47.Richeldi L, Ewer K, Losi M, Bergamini BM, Roversi P, Deeks J, et al . T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 2004; 170 :288-95.  Back to cited text no. 47    
48.Kendig EL, Jr. Kirkpatrick BV, Carter WH, Hill FA, Caldwell K, Entwistle M. Underreading of the tuberculin skin test reaction. Chest 1998; 113 :1175-7.  Back to cited text no. 48    
49.Arend SM, Engelhard AC, Groot G, de Boer K, Andersen P, Ottenhoff TH, et al . Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis-specific and nonspecific antigens for detection of latent infection in persons with recent tuberculosis contact. Clin Diagn Lab Immunol 2001; 8 :1089-96.  Back to cited text no. 49    
50.Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P, et al . Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 2003; 31 :347-53.  Back to cited text no. 50    
51.Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159 :15-21.  Back to cited text no. 51  [PUBMED]  [FULLTEXT]
52.Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, et al . Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38 :966-73.  Back to cited text no. 52    


Figures

[Figure - 1], [Figure - 2], [Figure - 3], [Figure - 4]

Tables

[Table - 1], [Table - 2]

This article has been cited by
1 Synergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosy
R. M. Oliveira,E. M. Hungria,A. Ara˙jo Freitas,A. L. O. M. Sousa,M. B. Costa,S. G. Reed,M. S. Duthie,M. M. A. Stefani
European Journal of Clinical Microbiology & Infectious Diseases. 2014;
[Pubmed] | [DOI]
2 Performance of Tuberculin Skin Test Compared to QFT-IT to Detect Latent TB Among High-risk Contacts in Mexico
Carmen Judith Serrano-Escobedo,JosÚ Antonio Enciso-Moreno,Joel Monßrrez-Espino
Archives of Medical Research. 2013; 44(3): 242
[Pubmed] | [DOI]
3 Tuberculin skin test and QuantiFERON in children
Bua, A. and Molicotti, P. and Cannas, S. and Ruggeri, M. and Olmeo, P. and Zanetti, S.
New Microbiologica. 2013; 36(2): 153-156
[Pubmed]
4 Performance of Tuberculin Skin Test Compared to QFT-IT to Detect Latent TB Among High-risk Contacts in Mexico
Serrano-Escobedo, C.J. and Enciso-Moreno, J.A. and Monárrez-Espino, J.
Archives of Medical Research. 2013; 44(3): 242-248
[Pubmed]
5 Sensitivity of QuantiFERON-TB GOLD In-Tube for diagnosis of recent versus remote M. tuberculosis infection
Bautista, J. and Banaei, N.
Diagnostic Microbiology and Infectious Disease. 2012; 73(3): 257-259
[Pubmed]
6 Role of biological therapy for inflammatory bowel disease in developing countries
Rogler, G. and Bernstein, C.N. and Sood, A. and Goh, K.L. and Yamamoto-Furusho, J.K. and Abbas, Z. and Fried, M.
Gut. 2012; 61(5): 706-712
[Pubmed]
7 Sensitivity of QuantiFERON-TB GOLD In-Tube for diagnosis of recent versus remote M. tuberculosis infection
Jemianne Bautista,Niaz Banaei
Diagnostic Microbiology and Infectious Disease. 2012; 73(3): 257
[Pubmed] | [DOI]
8 The effect of antituberculosis treatment on interferon-╬│ release assay results
Bugiani, M. and Bonora, S. and Carosso, A. and Piccioni, P. and Cavallero, M. and Mondo, A. and Ghisetti, V.
Monaldi Archives for Chest Disease - Pulmonary Series. 2011; 75(4): 215-219
[Pubmed]
9 Diagnosis & treatment of tuberculosis in HIV co-infected patients
Padmapriyadarsini, C. and Narendran, G. and Swaminathan, S.
Indian Journal of Medical Research. 2011; 134(12): 850-865
[Pubmed]
10 Interferon-gamma release assay for detection of latent tuberculosis infection in casual and close contacts of tuberculosis cases [test de quantification de la lib├ęration dŠinterf├ęron gamma pour le d├ępistage des infections tuberculeuses latentes chez les contacts occasionnels et rapproch├ęs des patients atteints de tuberculose]
Abu-Taleb, A.M.F. and El-Sokkary, R.H. and El Tarhouny, S.A.
Eastern Mediterranean Health Journal. 2011; 17(10): 749-753
[Pubmed]
11 Role of quantiFERON-TB test in detection of children infected with mycobacterium tuberculosis
Khalilzadeh, S. and Hassanzad, M. and Boloorsaz, M.R. and Baghaie, N. and Taheri, Z.M. and Velayati, A.A.
Tanaffos. 2010; 9(3): 22-27
[Pubmed]
12 Novel multiplex PCR using dual-priming oligonucleotides for detection and discrimination of the Mycobacterium tuberculosis complex and M. bovis BCG
Lee, H.R. and Kim, S.Y. and Chang, H.E. and Song, S.H. and Lee, H.S. and Park, K.U. and Song, J. and Kim, E.-C.
Journal of Clinical Microbiology. 2010; 48(12): 4612-4614
[Pubmed]
13 Diagnosis of tuberculosis in an era of HIV pandemic: A review of current status and future prospects
Chaudhary, M. and Gupta, S. and Khare, S. and Lal, S.
Indian Journal of Medical Microbiology. 2010; 28(4): 281-289
[Pubmed]
14 Future prospects for the utility of interferon assays in tuberculosis diagnosis
Saleem, T. and Syed, M. and Jamil, B.
Journal of the Pakistan Medical Association. 2010; 60(8): 704
[Pubmed]
15 Pediatric tuberculosis: Global overview and challenges
Swaminathan, S. and Rekha, B.
Clinical Infectious Diseases. 2010; 50(SUPPL. 3): S184-S194
[Pubmed]
16 HIV - Tuberculosis in children - Combating the deadly duo!
Muralidhar, S., Nair, D.
Journal of Pediatric Infectious Diseases. 2010; 5(1): 9-20
[Pubmed]
17 Rapid identification of tuberculosis epididymo-orchitis by INNO-LiPA Rif TB and QuantiFERON-TB Gold In Tube tests: Case report
Paluch-Oleś, J., Magryś, A., Kot, E., Kozioł-Montewka, M.
Diagnostic Microbiology and Infectious Disease. 2010; 66(3): 314-317
[Pubmed]
18 Usefulness of the QuantiFERON-TB-Gold <i>in tube</i> in a population at risk of bovine tubercular infection
Alessandra Bua, Paola Molicotti, Sara Cannas, Marina Cubeddu, Melania Ruggeri, S. Contena, R. Delogu, Stefania Zanetti
Acta Microbiologica et Immunologica Hungarica. 2010; 56(4): 369-373
[Pubmed] | [DOI]
19 Rapid identification of tuberculosis epididymo-orchitis by INNO-LiPA Rif TB and QuantiFERON-TB Gold In Tube tests: case report
Jolanta Paluch-Oles,Agnieszka Magrys,Ewa Kot,Maria Koziol-Montewka
Diagnostic Microbiology and Infectious Disease. 2010; 66(3): 314
[Pubmed] | [DOI]
20 Novel multiplex PCR using dual-priming oligonucleotides for detection and discrimination of the Mycobacterium tuberculosis complex and M. bovis BCG
Lee, H.R., Kim, S.Y., Chang, H.E., Song, S.H., Lee, H.S., Park, K.U., Song, J., Kim, E.-C.
Journal of Clinical Microbiology. 2010; 48(12): 4612-4614
[Pubmed]
21 Diagnosis of tuberculosis in an era of HIV pandemic: A review of current status and future prospects
Chaudhary, M., Gupta, S., Khare, S., Lal, S.
Indian Journal of Medical Microbiology. 2010; 28(4): 281-289
[Pubmed]
22 Future prospects for the utility of interferon assays in tuberculosis diagnosis
Saleem, T., Syed, M., Jamil, B.
Journal of the Pakistan Medical Association. 2010; 72(8): 704
[Pubmed]
23 Pediatric tuberculosis: Global overview and challenges
Swaminathan, S., Rekha, B.
Clinical Infectious Diseases. 2010; 50(sup 3): s184-s194
[Pubmed]
24 QuantiFERON-TB GOLD ELISA assay for the detection of Mycobacterium tuberculosis-specific antigens in blood specimens of HIV-positive patients in a high-burden country
Veldsman, C., Kock, M.M., Rossouw, T., Nieuwoudt, M., Maeurer, M., Hoosen, A.A., Ehlers, M.M.
FEMS Immunology and Medical Microbiology. 2009; 57(3): 269-273
[Pubmed]
25 In vitro levels of interleukin 10 (IL-10) and IL-12 in response to a recombinant 32-kilodalton antigen of Mycobacterium bovis BCG after treatment for tuberculosis
Priya, V.H.S., Anuradha, B., Gaddam, S.L., Hasnain, S.E., Murthy, K.J.R., Valluri, V.L.
Clinical and Vaccine Immunology. 2009; 16(1): 111-115
[Pubmed]
26 Using of T-Spot.<i>TB</i> and <i>Mantoux</i> tests in diagnosis of <i>M. tuberculosis</i> infection in BCG vaccinated children aged five and younger
Iveta Ozere, Ģirts Skenders, Iveta Līduma, Olga Bobrikova, Zita Lauska, Anita Skangale, Anita Jagmane, Vita Kalniņa, Vaira Leimane
Proceedings of the Latvian Academy of Sciences Section B Natural Exact and Applied Sciences. 2009; 63(6): 257-263
[Pubmed] | [DOI]
27 Pň tide ň pensjonere tuberkulintestene?
Storla, D.G.
Tidsskrift for den Norske Laegeforening. 2009; 129(24): 2618-2619
[Pubmed]
28 Tuberculin conversion and leukocyte migration inhibition test after BCG vaccination in newborn infants
Faridi, M.M.A., Kaur, S., Krishnamurthy, S., Kumari, P.
Human Vaccines. 2009; 5(10): 690-695
[Pubmed]
29 Prevalence of latent tuberculosis infection among health care workers in a hospital for pulmonary diseases
Schablon, A.
Journal of Occupational Medicine and Toxicology. 2009; 4(1): Art 4
[Pubmed]
30 Usefulness of the QuantiFERON-TB-Gold in tube in a population at risk of bovine tubercular infection
Bua, A. and Molicotti, P. and Cannas, S. and Cubeddu, M. and Ruggeri, M. and Contena, S. and Delogu, R. and Zanetti, S.
Acta Microbiologica et Immunologica Hungarica. 2009; 56(4): 369-373
[Pubmed]
31 P├ą tide ├ą pensjonere tuberkulintestene?
Storla, D.G.
Tidsskrift for den Norske Laegeforening. 2009; 129(24): 2618-2619
[Pubmed]
32 Using of T-Spot.TB and Mantoux tests in diagnosis of M. tuberculosis infection in BCG vaccinated children aged five and younger
Ozere, I. and Skenders, ─ó. and Liduma, I. and Bobrikova, O. and Lauska, Z. and Skangale, A. and Jagmane, A. and Kalni┼ća, V. and Leimane, V.
Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences. 2009; 63(6): 257-263
[Pubmed]
33 Evaluation of the interferon-╬│ release assay in healthcare workers
Nienhaus, A. and Schablon, A. and Le Bâcle, C. and Siano, B. and Diel, R.
International Archives of Occupational and Environmental Health. 2008; 81(3): 295-300
[Pubmed]
34 Using IFN-╬│ as a biomarker for detecting exposure to viral pathogens
Li, L. and Dufour, A.P.
Current Microbiology. 2008; 56(1): 84-88
[Pubmed]
35 Interferon gamma assays for tuberculosis in children
Rehman, A., Irfanullah
Journal of the Pakistan Medical Association. 2008; 58(9): 508-511
[Pubmed]
36 Pulmonary tuberculosis in a young pregnant female: Challenges in diagnosis and management
Maddineni, M., Panda, M.
Infectious Diseases in Obstetrics and Gynecology 2008. 2008; Art 628985
[Pubmed]
37 Interferon-gamma release assay for the diagnosis of latent TB infection - Analysis of discordant results, when compared to the tuberculin skin test
Nienhaus, A., Schablon, A., Diel, R.
PLoS ONE. 2008; 3(7): Art e2665
[Pubmed]
38 Performance of QuantiFERON-TB Testing in a Tuberculosis Outbreak at a Primary School
Molicotti, P., Bua, A., Mela, G., Olmeo, P., Delogu, R., Ortu, S., Sechi, L.A., Zanetti, S.
Journal of Pediatrics. 2008; 152(4): 585-586
[Pubmed]
39 Evaluation of the interferon-γ release assay in healthcare workers
Nienhaus, A., Schablon, A., Le BÔcle, C., Siano, B., Diel, R.
International Archives of Occupational and Environmental Health. 2008; 81(3): 295-300
[Pubmed]
40 Using IFN-γ as a biomarker for detecting exposure to viral pathogens
Li, L., Dufour, A.P.
Current Microbiology. 2008; 56(1): 84-88
[Pubmed]
41 Performance of QuantiFERON-TB Testing in a Tuberculosis Outbreak at a Primary School
Paola Molicotti,Alessandra Bua,Graziella Mela,Paolina Olmeo,Renzo Delogu,Silvia Ortu,Leonardo Antonio Sechi,Stefania Zanetti
The Journal of Pediatrics. 2008; 152(4): 585
[Pubmed] | [DOI]
42 Using IFN-? as a Biomarker for Detecting Exposure to Viral Pathogens
Lu Li,Alfred P. Dufour
Current Microbiology. 2008; 56(1): 84
[Pubmed] | [DOI]
43 Latent tuberculosis infection in healthcare workers - Evaluation of an interferon-γ release assay | [Latente tuberkulose-infektionen im gesundheitswesen - Evaluation des interferon-γ release assay]
Nienhaus, A., Loddenkemper, R., Hauer, B., Wolf, N., Diel, R.
Pneumologie. 2007; 61(4): 219-223
[Pubmed]
44 Genetic diversity of pathogenic microorganisms and its medical and public health significance
Virdi, J.S., Gulati, P., Pai, M.
Indian J Med Microbiol. 2007; 25(1): 2-3
[Pubmed]
45 Evaluation of the interferon-? release assay in healthcare workers
A. Nienhaus,A. Schablon,C. Le BÔcle,B. Siano,R. Diel
International Archives of Occupational and Environmental Health. 2007; 81(3): 295
[Pubmed] | [DOI]
46 Comparison of a whole blood interferon-? assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India
Sandeep Dogra,Pratibha Narang,Deepak K. Mendiratta,Pushpa Chaturvedi,Arthur L. Reingold,John M. Colford,Lee W. Riley,Madhukar Pai
Journal of Infection. 2007; 54(3): 267
[Pubmed] | [DOI]
47 The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression
Steven C. Derrick,Sheldon L. Morris
Cellular Microbiology. 2007; 9(6): 1547
[Pubmed] | [DOI]
48 Latent tuberculosis diagnosis in rheumatoid arthritis | [Abordagem diagnˇstica da tuberculose latente na artrite reumatˇide]
Marques, C.D.L., Duarte, A.L.B.P., Cavalcanti, F. de S., Freese de Carvalho, E.M., Gomes, Y. de M.
Revista Brasileira de Reumatologia. 2007; 47(6): 424-430
[Pubmed]
49 The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression
Derrick, S.C., Morris, S.L.
Cellular Microbiology. 2007; 9(6): 1547-1555
[Pubmed]
50 Comparison of tuberculin skin test and a specific T-cell-based test, T-SpotÖ.TB, for the diagnosis of latent tuberculosis infection
Ozekinci, T., Ozbek, E., Celik, Y.
Journal of International Medical Research. 2007; 35(5): 696-703
[Pubmed]
51 Follow-up study of tuberculosis-exposed supermarket customers with negative tuberculin skin test results in association with positive gamma interferon release assay results
Franken, W.P.J., Koster, B.F.P.J., Bossink, A.W.J., Thijsen, S.F.T., Bouwman, J.J.M., Van Dissel, J.T., Arend, S.M.
Clinical and Vaccine Immunology. 2007; 14(9): 1239-1241
[Pubmed]
52 Latent tuberculosis diagnosis in rheumatoid arthritis [Abordagem diagn├│stica da tuberculose latente na artrite reumat├│ide]
Marques, C.D.L. and Duarte, A.L.B.P. and Cavalcanti, F. de S. and Freese de Carvalho, E.M. and Gomes, Y. de M.
Revista Brasileira de Reumatologia. 2007; 47(6): 424-430
[Pubmed]
53 Comparison of tuberculin skin test and a specific T-cell-based test, T-SpotÔäó.TB, for the diagnosis of latent tuberculosis infection
Ozekinci, T. and Ozbek, E. and Celik, Y.
Journal of International Medical Research. 2007; 35(5): 696-703
[Pubmed]
54 Latent tuberculosis infection in healthcare workers - Evaluation of an interferon-╬│ release assay [Latente tuberkulose-infektionen im gesundheitswesen - Evaluation des interferon-╬│ release assay]
Nienhaus, A. and Loddenkemper, R. and Hauer, B. and Wolf, N. and Diel, R.
Pneumologie. 2007; 61(4): 219-223
[Pubmed]
55 Comparison of a whole blood interferon-╬│ assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India
Dogra, S. and Narang, P. and Mendiratta, D.K. and Chaturvedi, P. and Reingold, A.L. and Colford Jr., J.M. and Riley, L.W. and Pai, M.
Journal of Infection. 2007; 54(3): 267-276
[Pubmed]
56 Synthesis: Diagnosis of tuberculosis [Synth├Ęse: Diagnostic de la tuberculose]
Revue des Maladies Respiratoires. 2006; 23(1 C2): 2S33-2S34
[Pubmed]
57 New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis
Madhukar Pai, Shriprakash Kalantri, Keertan Dheda
Expert Review of Molecular Diagnostics. 2006; 6(3): 413
[VIEW] | [DOI]
58 New Diagnostic Methods for Mycobacterium Tuberculosis Infection
Dong Ho Shin
Journal of the Korean Medical Association. 2006; 49(9): 773
[VIEW] | [DOI]
59 Specimen collection methods in the diagnosis of childhood tuberculosis
Marais, B.J., Pai, M.
Indian J Med Microbiol. 2006; 24(4): 249-251
[Pubmed]
60 Advances in the diagnosis and treatment of tuberculosis
Nahid, P., Pai, M., Hopewell, P.C.
Proceedings of the American Thoracic Society. 2006; 3(1): 103-110
[Pubmed]
61 API TB consensus guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations
Joshi, J.M., Vijayan, V.K., Jindal, S.K., Jagganath, K., Rodrigues, C., Gupta, S.B.
Journal of Association of Physicians of India. 2006; 54(Mar): 219-234
[Pubmed]
62 Synthesis: Diagnosis of tuberculosis | [Synthèse: Diagnostic de la tuberculose
Revue des Maladies Respiratoires. 2006; 23(1 C2): 2S33-2S34
[Pubmed]
63 SynthŔse : diagnostic de la tuberculose
Revue des Maladies Respiratoires. 2006; 23(1): 33
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
Previous article Next article

    

ę 2004 - Indian Journal of Medical Microbiology
Published by Wolters Kluwer - Medknow

Online since April 2001, new site since 1st August '04